Access options for withdrawn motility-modifying agents

Abstract

Physicians caring for patients with motility or functional digestive diorders often decry the unhappy state of prokinetic therapy. There appears to be a paucity of agents brought to market and several of the agents felt to be truly efficacious have been withdrawn. While treatment options remain limited, the scenario may not be as bleak as initially thought. Treatment options are available particularly if practitioners are willing to pursue alternative prescribing approaches. This article describes mechanisms by which physicians may safely obtain prokinetic agents commonly regarded as inaccessible.